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Abstract. Plakoglobin is a major component of the 
submembranal plaque of adherens junctions and des- 
mosomes in mammalian ceils. It is closely related to the 
Drosophila segment polarity gene armadillo which has 
a role in the transduction of transmembrane signals 
that regulate cell fate. Like its close homologue [3-cate- 
nin, plakoglobin can associate with the product of the 
tumor suppressor gene APC that is linked to human co- 
lon cancer. We have studied the effect of plakoglobin 
overexpression, and the cooperation between plakoglo- 
bin and N-cadherin, on the morphology and tumori- 
genic ability of cells either lacking, or expressing cad- 
herin and eL- and 6-catenin. 
Overexpression of plakoglobin in SV40-transformed 
3T3 (SVT2) cells suppressed the tumorigenicity of the 
cells in syngeneic mice. Transfection with N-cadherin 
conferred an epithelial phenotype on the cell culture, 
but had no significant effect on the tumorigenicity of 
the cells. Cotransfection of plakoglobin and N-cadherin 
into SVT2 cells, however, was considerably more effec- 
tive in tumor suppression than plakoglobin overexpres- 
sion alone. Finally, transfection of plakoglobin into a 
human renal carcinoma cell line that expresses neither 
cadherins nor plakoglobin, or or- and 13-catenin,  re- 
sulted in a dose-dependent suppression of tumor for- 
mation by these cells in nude mice. Plakoglobin, in 
these cells, did not exhibit junctional localization and 
was diffusely distributed in the cytoplasm, with a signif- 
icant amount of the protein also localized in the nu- 
cleus. The results suggest that plakoglobin can effi- 
ciently suppress the tumorigenicity of cells in the 
presence of, or independently of the cadherin-catenin 
complex. 
ECENT studies have established that the modulation 
of cell adhesion, using genetic or immunochemical 
approaches, could exert a major effect on the inva- 
sive or metastatic potential of tumor cells. Overexpression 
of various junctional molecules, including the adhesion re- 
ceptor molecules integrin and cadherin,  and the  plaque 
proteins vinculin and et-actinin, was shown to increase the 
adhesiveness of the transfected cells and effectively sup- 
press their tumorigenicity (Behrens et al., 1989; Rodrfguez 
Fern~indez et al., 1992a,b; Gltick et al., 1993; Vleminckx et 
al., 1991; Navarro et al., 1991; Frixen et al., 1991; Giancotti 
and Rouslahti, 1990; Tsukita et al., 1993).  This suggests 
that a highly adhesive phenotype may not be compatible 
with malignant growth. Similarly, antibody-mediated inhi- 
bition of cell adhesion and antisense suppression of junc- 
tional protein expression led to a decrease in cell adhesion, 
and, consequently, to an increase in tumorigenic capacity 
(Behrens et al., 1989; Vleminckx et al., 1991; Rodriguez 
Fernandez et al., 1993; Gliick and Ben-Ze'ev, 1994). 
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In the present study, we have investigated the ability of 
plakoglobin,  a  major  constituent  of  the  submembrane 
plaque of cell-cell adherens junctions (Cowin et al., 1986) 
to affect tumorigenicity, when overexpressed either alone, 
or in conjunction with cadherins. We have chosen to study 
plakoglobin for the following reasons: (a) Previous studies 
on the potential role of junctional plaque components in 
tumor suppression were conducted with proteins associ- 
ated with both cell-cell and cell-matrix adhesions. It was 
therefore  of  interest  to  determine  whether  molecules 
which  are  uniquely  associated  with  cell-cell  junctions 
(such as plakoglobin), could have a similar effect. (b) Re- 
cent studies have suggested that malignant transformation, 
in certain tumor cell lines, correlates with reduced plako- 
globin expression  (Navarro  et al.,  1993; Sommers et al., 
1994). (c) In addition, plakoglobin is closely related to the 
Drosophila segment polarity gene armadillo (Peifer and 
Weischaus, 1990; Peifer et al.,  1992)  which was demon- 
strated to function in the transduction of transmembrane 
signals that regulate cell fate (Bejsovec and Wieschaus, 
1993). (d) Plakoglobin, like its close homologue 13-catenin 
(Suet al., 1993; Rubinfeld et al., 1993), can associate with 
the product of the tumor suppressor gene APC (Shibata et 
al., 1994; Htilsken et al., 1994) that is linked to human co- 
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shown that the human plakoglobin gene that is closely lo- 
calized to the BRCA1 region on chromosome 17 is subject 
to loss  of heterozygosity in  sporadic breast  and  ovarian 
cancers (Aberle et al., 1995). 
To study the effect of plakoglobin on tumorigenicity in 
mammalian cells, transformed cells of both mouse and hu- 
man origin were transfected with plakoglobin cDNA and 
its effects on cell morphology and tumorigenicity were ex- 
amined.  The transfected cells displayed a  markedly sup- 
pressed ability to form tumors in syngeneic or nude mice 
when  compared to nontransfected controls. In  addition, 
the  differential effects on  tumor  formation,  exerted by 
overexpression of plakoglobin and N-cadherin, and the co- 
operation between these two proteins, were also investi- 
gated. SVT2 cells overexpressing N-cadherin displayed a 
more epitheloid morphology in culture, yet their tumori- 
genicity in vivo remained essentially unchanged. However, 
transfection  of  both  N-cadherin  and  plakoglobin  into 
SVT2 cells had  an  augmenting effect, and  resulted in  a 
more effective tumor suppression than with plakoglobin 
alone. Finally, plakoglobin could suppress  tumor forma- 
tion even by cells which do not express any adherens junc- 
tion and desmosomal proteins, including cadherins, cate- 
nins, desmoplakins, or plakoglobin. 
Materials and Methods 
Cell Culture and Transfection 
Balb/C 3T3 and SVT2 cells, which are Balb/C 3T3 cells transformed by 
SV40, MDCK, and A431 cells were all grown in Dulbecco's modified Ea- 
gle medium plus 10% calf serum (GIBCO BRL, Gaithersburg, MD). Re- 
nal carcinoma cell lines of the KTCTL series were obtained from Dr. M. 
ZOller (The German Cancer Research Center, Heidelberg, FRG). These 
lines were established from human renal tumors whose clinical and patho- 
logical characteristics were defined. The cells were grown in RPMI me- 
dium containing 10% calf serum. 
Cells were  transfected with  a  full-length human plakoglobin  cDNA 
(Franke et al., 1989) or the human N-cadherin (Salomon et al., 1992). The 
cDNAs were cloned into the EcoRI site of the polylinker of the pJ4fl ex- 
pression vector  (Rodrfguez Fern~indez et al., 1993)  that consists of the 
Mo-MuLV LTR promoter-enhancer sequence, the SV40 small t-antigen 
intron, and the SV40 large T  polyadenylation signal in the pBR322 plas- 
mid. The neomycin resistance (neo') 1 gene, which was cotransfected with 
the  pJ41~  construct  containing  the  full-length  human  plakoglobin  or 
N-cadherin, was subcloned into the pSVL expression vector. Transfection 
was carried out by the calcium phosphate precipitation method and colo- 
nies resistant to 800 ~g/ml G418  (Geneticin, Gibco) were isolated. The 
second gene was transfected together with the hygromycin-resistant (hy- 
gro  r) cDNA driven by the pGK promoter, and colonies resistant to 500 
txg/ml hygromycin (Calbiochem, San Diego, CA) were isolated. 
The ability of the different transfected clones to grow in suspension in 
soft agar was determined as described (Rodffguez Fermindez et al., 1993). 
The distribution of cells in the different phases of the cell cycle was de- 
termined by fluorescence-activated cell sorter analysis (FACS). Subcon- 
fluent cultures were permeabilized with 0.1% Triton X-100, stained with 
propidium iodide,  and  analyzed  using a  FACScan  cell  sorter  (Becton 
Dickinson, Mountain View, CA) and by applying the CellFit program to 
determine the percentage of cells in the various stages of the cell cycle. 
Immunofluorescence 
Cells were cultured on glass coverslips, fixed with 3.7% paraformaldehyde 
in phosphate buffered saline, and permeabilized with 0.5% Triton X-100. 
1. Abbreviations  used in this paper: hygro  r,  hygromycin resistant; neo  r, 
neomycin resistance; SVT2, SV40-transformed 3T3. 
A  monoclonal antibody against human plakoglobin PG5.1 (Cowin et al., 
1986), obtained from Dr. W.W. Franke (The German Cancer Research Cen- 
ter, Heidelberg, FRG), and another monoclonal antibody against human 
plakoglobin, lIE4, a gift from Dr. M. Wheelock (The University of To- 
ledo, OH), were used. The secondary antibody was rhodamine-labeled goat 
anti-mouse IgG (Jackson ImmunoResearch  Laboratories, West Grove, PA). 
The cells were examined by epifluorescence with a Zeiss Axiophot micro- 
scope. For vinculin staining we used the anti-human h-VIN1 antibody from 
Sigma Chem. Co. (St. Louis, MO), and rhodamine-phalloidin for visualiz- 
ing F-actin. 
Immunoblotting and Polyacrylamide 
Gel Electrophoresis 
Equal amounts of total cell protein from the different clones in Laemmli's 
buffer (Laemmli, 1970)  were separated by PAGE, electro-transferred to 
nitrocellulose, and incubated with the monoclonal anti-plakoglobin anti- 
bodies, an antibody to human N-cadherin (13A9), anti--ct-catenin (1G5), 
anti-[3-catenin  (5H10),  anti-desmocollin  2  (7D6),  anti-desmoglein  2 
(6D8), all provided very generously by Dr. M. Wheelock, or the Pan-cad- 
herin antibody recognizing a  common epitope  to  all classical cadherins 
(Sigma, Israel), followed by anti-mouse IgG. The anti-desmoplakin anti- 
body 2.15, recognizing desmoplakin II, was provided by Dr. W.W. Franke. 
The antigens were visualized by the enhanced chemiluminescence (ECL) 
method  (Amersham, Buckinghampshire, UK),  and  the  density of the 
bands  quantitatively  determined  by  laser  densitometry  using the  Im- 
ageQuant software. 
Cells were  also fractionated into Triton X-100 soluble and insoluble 
fractions as described (Rodrfguez Fern~indez et al., 1992b),  and equal vol- 
umes of each fraction were analyzed by immunoblotting. 
Southern and Northern Blot Analysis 
Total  RNA  was  extracted  from  cells  by  the  guanidinium thiocyanate 
method (Chomczynski and Sacchi, 1987), Northern blots containing 20 Ixg 
per lane of total RNA were stained with methylene blue to determine the 
position of 18S and 28S rRNA markers, and then hybridized with plako- 
globin cDNA, which was labeled with [3ZP]dCTP by the random priming 
technique (Feinberg and Vogelstein, 1983). Southern blots with EeoRI di- 
gests of DNA from the different clones were hybridized with the plako- 
globin cDNA probe as described (Gltick et al., 1993). 
Tumorigenicity Assay 
SVT2  and  human renal  carcinoma cells  were  injected  subcutaneously 
(s.c.) into syngeneic Balb/C mice and CD-1 nu/nu athymic nude mice, re- 
spectively (with 5 x  105, 106, or 5 x  106 cells per animal). The appearance 
and size of tumors and survival time of the mice were  examined three 
times a week. The tumors were excised and examined histologically after 
HE staining. In addition, frozen sections of the excised tumors were im- 
munostained with antibodies to plakoglobin, N-cadherin, and vinculin. 
Results 
Suppression of Tumorigenicity in SVT2 Cells 
Transfected with Plakoglobin 
To  study  the  effect  of  plakoglobin  on  tumorigenicity,  a 
highly malignant  SV40-transformed  3T3  cell  line,  SVT2, 
was  chosen since it does  not express  detectable  levels  of 
this protein (Fig. 1 A), while expressing et- and [3-catenin 
and N-cadherin (Figs.  1 C and 2 A). In contrast, 3T3 cells 
express significant levels of plakoglobin (Fig. 1, A  and B). 
SVT2 cells were cotransfected with a full-length plakoglo- 
bin and the neo' cDNAs and G418-resistant colonies were 
isolated. Western blots of equal amounts of total cell pro- 
tein from such clones were  incubated with anti-plakoglo- 
bin  antibody and several  SVT2  clones  expressing  plako- 
globin  at  different  levels  were  identified  (Fig.  I  A). 
Southern blot hybridization indicated that multiple copies 
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positive clones (data not shown), and Northern  blot hy- 
bridization with the plakoglobin cDNA showed a correla- 
tion between the level of the plakoglobin protein and RNA 
in the different transfected SVT2 clones (Fig. 1 B). 
The forced expression of plakoglobin in SVT2 cells did 
not lead to gross changes in cell shape (Fig. 1, D and F), or 
actin and vinculin organization (data not shown). Immu- 
nofluorescent staining revealed, however, that the trans- 
fected plakoglobin was localized at cell-cell junctions (Fig. 
1 G), indicating that the other junctional protein(s), neces- 
sary for the interaction of plakoglobin with the membrane 
were available within the cells. 
To study the effect of plakoglobin overexpression on the 
tumorigenic phenotype,  the  ability of SVT2  clones  ex- 
pressing different levels of plakoglobin to grow in soft agar 
and the formation of tumors in syngeneic mice were exam- 
ined (Table I). While no significant differences were obtained 
in the cloning efficiency  in agar of the various plakoglobin- 
expressing SVT2 clones (~23%  colony formation), there 
was a dramatic inhibition of tumorigenicity  in cells express- 
ing high levels of plakoglobin (Table I). This inhibition cor- 
responded to the level of plakoglobin expressed: i.e., the 
clone  expressing  the  highest  plakoglobin  level  was  the 
least tumorigenic, while the clone expressing only low lev- 
els  of plakoglobin  was  as  tumorigenic  as  the  parental 
SVT2 (Table I). 
Augmenting Action of N-Cadherin and Plakoglobin in 
the Inhibition of Tumorigenicity 
To investigate the possible cooperation between cadherin 
and  plakoglobin  in  suppressing  the  tumorigenicity  of 
SVT2 cells, N-cadherin was overexpressed in these cells, 
either alone, or together with plakoglobin (Fig. 2). Unlike 
3T3 cells, SVT2 cells express low levels of N-cadherin (Fig. 
2  A,  compare  lanes  1  and  4).  After  transfection  with 
N-cadherin  eDNA,  colonies  expressing  increased  levels 
(up to 14-fold higher than control SVT2, see Table II) of 
N-cadherin were obtained (Fig. 2 A, CAD1 and CAD2). 
These clones gained an epithelial morphology (Fig. 3 A), 
with N-cadherin, a-, and [3-catenin present at cell-cell bor- 
ders (Figs. 2 B, 3, B and C). Immunoblot analysis with an- 
tibodies to {3-catenin revealed that the level of this protein 
increased in the N-cadherin overexpressing clones (Fig.  2 
A). The tumorigenic ability of SVT2 clones overexpressing 
N-cadherin was, however, not significantly affected when 
Table I. Tumorigenicity of  Plakoglobin-transfected SVT2 Cells 
Cell line  Tumor incidence  PG level* 
SVT2  5/5  0 
N 1  5/5  0 
PG 1  4/5  3.5 
PG2  3/5  12.8 
PG3  3/5  14.2 
PG4  1/5  110.7 
Groups of five Balb/C syngeneic mice were injected with 3 ×  106 cells/mouse  and the 
development of tumors was followed for 3 mo. Animals with tumors died within 4-5 
wk, while the tumor-free animals did not develop tumors even after 3 mo when the ex- 
periment was terminated. 
NI, neo  r SVT2 control. 
*The levels of plakoglobin  were delermined by densitometer  scanning  of the gel 
shown in Fig.  1 A and taking the value of MDCK ceils as 100%. 
compared to parental SVT2 cells, or to hygro  r control cells 
(Table II). This is in sharp contrast to the plakoglobin-trans- 
fected cells which did not show an increase in neither a- or 
[3-catenin, nor in cadherin expression (Figs. 1 A and 2 A), 
but efficiently suppressed the tumorigenic ability of cells 
(Table I). In addition, growth in agar indicated that the 
cadherin-transfected cells  remained  anchorage  indepen- 
dent, like the parental, nontransfected cells (Fig. 4). 
To  study  the  interrelationships  between  plakoglobin 
(which does not induce shape changes, but is tumor sup- 
pressive)  and N-cadherin (which causes epithelialization, 
but  does  not  reduce  tumorigenicity), we  have  double- 
transfected SVT2 cells with cDNAs encoding the two pro- 
teins (Fig. 2 A, CAD/PG1-5). The morphology of the dou- 
ble overexpressing clones was variable (Fig. 3 D), largely 
reflecting differences in the level of cadherin expressed by 
the cells (Table II). Immunofluorescence analysis of these 
clones  invariably  showed  that  plakoglobin  and  N-cad- 
herin, as well as ct- and 13-catenin were enriched at cell-cell 
junctions (Fig. 2, D and E, 3, E and F). In addition, in cells 
doubly transfected with plakoglobin and N-cadherin, the 
level  of Triton  X-100  insoluble  plakoglobin was  higher 
than in cells transfected with plakoglobin alone (Fig. 2 A, 
54% vs 42%, in CAD/PG3 vs PG3). These cells also dis- 
played a  drastically reduced tumorigenicity as compared 
to either control SVT2, or even to the clones expressing 
plakoglobin alone (Table II). Examination of colony for- 
mation by the different clones in soft agar revealed that 
while the number of colonies in agar was similar to that of 
SVT2 cells, or of cells overexpressing the individual pro- 
teins, the size of the colonies in the double transfectants 
was significantly smaller (Fig. 4 D), suggesting a decrease 
in growth rate. The results summarized in Fig. 5 demon- 
strate that cells transfected with either plakoglobin or cad- 
herin  have  a  slower  growth  rate  than  control-untrans- 
fected cells and that double-transfected clones show the 
slowest proliferation. Possible changes in cell cycle in the 
different clones was directly investigated by flow cytome- 
try (Table Ili). The less tumorigenic clones contained a 
smaller number of cells in the S phase and an increased 
number of cells in the G1 and G2 phase, with the double- 
Table II. Tumorigenicity of  Plakoglobin- and 
N-Cadherin-transfected SVT2 Cells 
Transfected  with 
Cell line  Tumor incidence  PG  N-CAD 
SVT2  5/5  -  (0)*  -  (77)* 
H1  5/5  -  (0)  -  (83) 
CAD1  5/5  -  (0)  +  (823) 
CAD2  5/5  -  (0)  +(1104) 
PG3  3/5  -  (874)  -  (38) 
CAD/PG1  1/5  +  (571)  +  (574) 
CAD/PG2  1/5  +  (291)  +  (486) 
CAD/PG3  1/5  +(1281)  +  (469) 
CAD/PG4  1/5  +  (397)  +  (442) 
Groups of five syngeneic Balb/C mice were injected s.c. with 3 ×  106 cells of the dif- 
ferent clones and the development of tumors after 3 wk is shown. After 3 mo the ani- 
mals without tumors remained tumor-free,  while those with tumors died ~4-5 wk af- 
ter injection.  HI, hygro' SVT2 control;  CAD, N-cadherin-transfected SVT2;  PG, 
plakoglobin-transfected  SVT2;  CAD/PG,  double-transfected  SVT2 with N-cadherin 
and plakoglobin. 
*The numbers in parentheses  are arbitrary units representing  the levels of expression 
of the transgenes after densitometer  scanning of the gels shown in Fig. 2 A. 
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ern blot, and immunofluores- 
cence  analysis  of  SV'I2 
clones  transfected  with  pla- 
koglobin. G418-resistant SVT2 
clones obtained after cotrans- 
fection with plakoglobin and 
the  neo  r  cDNAs  were  ana- 
lyzed by Western blotting us- 
ing  (A)  anti-plakoglobin 
(PG)  or  (C)  anti--a-catenin 
(a-CAT),  or  anti-13-catenin 
(13-CAT)  antibodies.  Note 
that  the  anti-human  plako- 
globin  antibody  recognizes 
the  mouse  plakoglobin  in 
3T3 cells and the canine mol- 
ecule  in  MDCK  cells.  (B) 
Northern  blot  hybridization 
of  RNA  from  plakoglobin- 
transfected  SVT2  clones, 
MDCK,  and  3T3  cells.  The 
level  of  28S  rRNA  in  the 
same  blot  is  shown  after 
methylene  blue  staining  of 
the blot. (D and F) Cell mor- 
phology and (E and G) pla- 
koglobin  organization,  by 
immunofluorescence,  were 
determined in SVT2 (D and 
E) and in plakoglobin-trans- 
fected cells  (F and  G).  The 
lanes in A are 1, MDCK cell 
extract (c); 2, SVT2 untrans- 
fected control; 3-15, individ- 
ual  neo  r  colonies.  PG1-4, 
individual  plakoglobin- 
expressing clones.  A431  is  a 
cell  line  from  human  carci- 
noma.  Bars:  (D  and  F)  50 
IxM; (E and G) 10 IxM. 
transfected  cells  displaying the greatest  effect. Taken to- 
gether,  these  data  suggest that  plakoglobin can suppress 
the  tumorigenicity  of  cells  when  overexpressed  either 
alone,  or  in  conjunction  with  N-cadherin,  and  that  the 
growth of the doubly transfected cells is reduced. 
Suppression  of Tumorigenicity  in Renal Carcinoma 
Cells by Plakoglobin  Transfection  in the Absence of 
Cadherins and a- and fl-Catenin 
The  augmenting effect of N-cadherin on the suppression 
of  tumorigenicity  in  plakoglobin-transfected  SVT2  cells 
raised the possibility that the effect of plakoglobin might 
be  attributable  to  increased  assembly  of adherens  junc- 
tions in the transfected cells. We, therefore, looked for tu- 
mor cell lines that lack all the major constituents of cell--cell 
adherens junctions including plakoglobin, et- and [3-catenins 
as well as cadherin, as candidates for transfection with pla- 
koglobin. Screening of a variety of cell lines derived from 
various  human  tumors  revealed  several  renal  carcinoma 
lines which lack all these proteins,  as well as the desmo- 
somal cadherins and desmoplakins (Fig. 6, A  and C). The 
clone selected for the present work (KTCTL 60) produced 
tumors with high efficiency in nude mice. The cells were 
cotransfected  with  the  human  plakoglobin  and  the  neo  r 
cDNAs and G418-resistant colonies were analyzed for ex- 
The Journal  of Cell Biology,  Volume 133, 1996  202 Figure 2.  Western blot and immunofluorescence analysis of SVT2 clones transfected with N-cadherin and plakoglobin. Cells were trans- 
fected with either N-cadherin alone (CAD1, 2), with plakoglobin alone (PG3), or with N-cadherin  after transfection  with plakoglobin 
(CAD/PG1-5), and individual hygro  r colonies were isolated.  (A) Equal amounts of total cell protein were analyzed by Western blotting 
with anti-N-cadherin (CAD), plakoglobin (PG), or 13-catenin (13-CAT) antibodi.es. The levels of N-cadherin in 3T3 (lane 1); CAD1 
(lane 2); CAD/PG1 (lane 3); SVT2 (lane 4) and the neo  r HI clone (lane 5) were compared. The levels of Triton X-100 soluble (s) and in- 
soluble (i) plakoglobin in several clones is shown. (B and C) The N-cadherin-transfected clone CAD1, and the N-cadherin  plus plako- 
globin-transfected  clone CAD/PG1 (D and E) were immunostained with anti-N-cadherin (B and D) or plakoglobin (C and E) antibod- 
ies. H1, hygror-transfected  control. The bars represent 10 ~M. 
pression of the transgene (Fig. 6 B). G418-resistant plako- 
globin negative clones, and several positive clones, includ- 
ing one that expressed high levels of the protein (No. 14, 
similar to  plakoglobin  levels in  MDCK  cells,  Fig.  6  B), 
were identified.  Eight  of these  clones were injected  into 
nude mice and the rate of tumor development (tumor di- 
ameter at different times after injection) determined (Fig. 
7).  While  all the clones, except one  (No.  14),  eventually 
formed tumors in nude mice, the rate of tumor formation 
was  inversely correlated  to  the  level  of plakoglobin  ex- 
Simcha et al. Plakoglobin and Tumor Suppression  203 Figure 3.  Immunofluorescence of N-cadherin and N-cadherin plus plakoglobin-transfected clones. (A-C) Cells transfected with N-cad- 
herin (done CAD1) or (D-F) with N-cadherin and plakoglobin (done CAD/PG1) were photographed while growing (A and D), or af- 
ter fixation and immunostaining with antibodies against 13-catenin  (B and E) or a-catenin (C and F). Bars: (A and D) 50 ~M; (B, C, E, 
and F) 10 ~M. 
pressed. Neo  r clones which did not express detectable lev- 
els of plakoglobin (clones 4 and 9, Fig. 6 B), formed large, 
anaplastic, and undifferentiated tumors within 10 d, while 
the tumors formed by clones expressing low levels of pla- 
koglobin (clones 1, 3,  11,  12,  and 13, Fig. 6 B) exhibited 
similar morphology (data not shown), yet developed sig- 
nificantly more slowly (Fig. 7). Clone 14 with a highest pla- 
koglobin level, comparable to  that  of MDCK  epithelial 
The Journal 9  f Cell Biology, Volume 133, 1996  204 Figure 4.  The growth in soft agar of SVT2 cells transfected with either plakoglobin,  N-cadherin,  or both N-cadherin  and plakoglobin. 
Cells were seeded (250 and 1,000 cells per 35-mm dish) in soft agar and the colonies were photographed 2 wk later.  (A) SVT2 control; 
(B) N-cadherin-transfected cells (clone CAD2); (C) plakoglobin-transfected cells (clone PG4); and (D) cells transfected with both 
N-cadherin and plakoglobin (clone CAD/PG1). The diameter of the colonies was smaller by 25% in N-cadherin transfectants,  by 30% 
in plakoglobin-transfected cells, and by 62% in the double transfectants.  The decrease in volume, assuming a spherical shape for the col- 
onies was 2.4-, 2.8-, and 17.7-fold, respectively. The bars represent 100 I~M. 
cells (Fig. 6  B),  did  not form any tumors in  the  injected 
mice (Fig. 7 B). Mice that were injected with cells from all 
the clones tested, except clone 14, developed large tumors 
and died within 2.5-3 wk after inoculation. No tumors ap- 
peared in mice injected with clone 14 even 3 mo after the 
injection.  The majority of plakoglobin in  the  transfected 
cells (84% in clone 14 and 82% in clone 13) was found in 
the Triton X-100 soluble fraction (Fig. 6 B). Immunofluo- 
rescence  analysis revealed  that  this plakoglobin was dif- 
fusely  distributed  in  the  cytoplasm,  and  a  significant 
amount of the protein was also detected in the nuclei of 
the transfected cells (Fig. 6 G). Taken together, the results 
indicate that plakoglobin can function as an effective tu- 
mor suppressor in both mouse and human tumor cell lines 
either alone, or together with the cadherin-catenin system. 
Table IlL The Effects of Plakoglobin and N-Cadherin 
Overexpression on Cell Cycle Distribution 
Cell cycle phase  HI*  CAD2*  PG3  §  CAD/PG 1  II 
% 
G1  63  -+ 2.6  71  -+ 2.2  75 -+ 2.0  81  --+  1.8 
S  32 -+ 2.1  23 ~  2.0  14 -+  1.0  9  ---  1.5 
G2  5  -+  1.3  6  -+  1.1  11  -  2.1  l0 -  0.8 
The values represent percent of transfected SVT2  cells in the different stages of the 
cell cycle determined by FACS analysis. 
* Control, hygromycinoresistant  cells (see Fig. 2 A). 
*N-cadherin-transfected  cells (CAD2, see Fig. 2 A). 
°Plakoglobin-transfected  cells (PG3, see Figs. 1 A and 2 A). 
IIN-cadherin- and plakoglobin4ransfected  cells (see Fig. 2 A and Table II). 
Sirncha et al. Plakoglobin and Tumor Suppression  205 "[+  H1  z  ] 
e- 
0  1  2  3  4  5 
Days 
Figure 5. The rate of growth of SVT2 clones transfected with ei- 
ther N-cadherin, plakoglobin, or both N-cadherin and plakoglo- 
bin. Cells were seeded at 5 × 105 cells per 60-mm dish and at the 
indicated times the number of viable ceils in tetraplicates was de- 
termined.  Similar results were obtained in four independent ex- 
periments. The levels of cadherin and plakoglobin expression by 
the different clones are described in Fig. 2 A and Table II. The 
growth curves of CAD/PG1-4 were very similar, therefore only 
one curve is shown. 
Discussion 
Previous studies have demonstrated that increasing the ex- 
pression  of  several  adherens  junction  plaque  proteins, 
such as vinculin and a-actinin, may considerably augment 
cell-ECM adhesion and consequently suppress the tumori- 
genicity of malignant  cells  (Rodriguez Fermindez et al., 
1992b; Gltick et al., 1993). It was further shown that tar- 
geted decrease in the expression of these proteins in non- 
tumorigenic 3T3 cells by antisense transfection can confer 
"anchorage  independence"  or  even tumor  formation in 
nude mice (Rodriguez Fern~indez et al., 1993; Gl0ck et al., 
1994).  These  and  additional  studies  of a  similar  nature 
(Cunningham et al., 1992; Prasad et al., 1993), suggested 
that increased cell adhesiveness, triggered by high levels of 
junctional plaque or microfilament proteins, may suppress 
the malignant properties of tumor cells and restore adhe- 
sion-mediated growth control. These studies however, did 
not indicate whether junctional molecules such as vinculin 
and a-actinin exert their tumor suppressing effect by influ- 
encing  cell-matrix  or  cell-cell  contacts,  nor  was  it  ex- 
cluded that soluble, rather than junctional association of 
such molecules, are responsible for affecting the tumorige- 
nicity of ceils. 
Plakoglobin was chosen for the present study since this 
protein is  exclusively associated with cell-cell adhesions 
(both  adherens  and  desmosomes,  Cowin  et  al.,  1986; 
Cowin,  1994)  and  was  implicated in  signal  transduction 
processes in Drosophila (Peifer et al.,  1991)  and Xenopus 
(Karnovsky and Klymkowsky, 1995). Moreover, the avail- 
ability  of  tumor  cells  which  lack  both  cadherins  and 
catenins, enabled us to determine whether junction forma- 
tion is necessary for tumor suppression. 
The results presented here demonstrate that expression 
of plakoglobin in various tumor cells, which lack this pro- 
tein,  results in  an  effective suppression  of their tumori- 
genic  ability in  vivo. This was  observed in  SV40-trans- 
formed  3T3  cells  (SVT2)  which  express  low  levels  of 
cadherin, and or- and 13-catenin, as well as in a human renal 
carcinoma cell line which expresses neither cadherins nor 
catenins  or  plakoglobin.  Interestingly, transfection with 
plakoglobin was not accompanied by significant changes 
in overall cell morphology or in the distribution of actin 
and vinculin in these cells. This was in contrast with the 
conspicuous effects on cell morphology exerted by trans- 
fection with vinculin (Rodrfguez Fern~indez et al., 1992b; 
Geiger et al.,  1992). In addition, plakoglobin-transfected 
SVT2  cells,  unlike  vinculin-  and  a-actinin-transfected 
SVT2 (Rodriguez Fermindez et  al.,  1992b;  G10ck et  al., 
1993),  remained  anchorage  independent  and  produced 
large colonies in soft agar. 
Transfection with N-cadherin, while leading to epithe- 
lialization of the cell culture, did not affect the tumorige- 
nicity of SVT2 cells, raising the possibility that the sup- 
pressive effect of plakoglobin on tumor formation may not 
require a  marked stimulation of cell--cell adhesion. This 
notion was strongly supported by the~esults obtained with 
transfected renal carcinoma cells which displayed neither 
adherens junctions nor desmosomes, yet their tumorige- 
nicity was effectively suppressed by plakoglobin overex- 
pression. Our results also support previous findings indi- 
cating that cadherin overexpression is not always sufficient 
for changing invasiveness and for suppressing tumor for- 
mation (Navarro et al., 1993;  Sommers et al., 1994). It is 
noteworthy, however, that  expression of N-cadherin,  in 
addition to plakoglobin, significantly enhances the tumor 
suppressive effect. This finding further supports the possi- 
bility that assembly of the junctional complex which con- 
tains cadherin, the catenins, and plakoglobin might be im- 
portant for signaling pathways that regulate cell growth. 
This hypothesis is consistent with the results showing a de- 
crease in the number of cells in S phase and the smaller 
size of the colonies formed in  soft agar by cells double 
transfected with plakoglobin and N-cadherin. 
By what mechanism is plakoglobin exerting its suppres- 
sive effect in the absence of cadherins and catenins? One 
possibility could be that plakoglobin might associate with 
other regulatory molecules, including the EGF receptor 
(Hoschuetzky et al., 1994) or the human tumor suppressor 
protein APC (Shibata et al., 1994; Hiilsken et al., 1994), in 
a cadherin- or 13-catenin-independent fashion (Htilsken et 
al.,  1994;  Knudsen  and  Wheelock,  1992;  Hinck  et  al., 
1994a). Thus, nonjunctional cytoplasmic or nuclear plako- 
globin could participate in signal transduction processes 
that eventually regulate cell growth. Recent genetic analy- 
sis  in Drosophila supports this notion, by demonstrating 
Figure 6.  Western blot and immunofluorescence analysis of plakoglobin in human renal carcinoma ceils. (A) The expression of plako- 
globin in cell lines established from different human renal carcinomas was determined by Western blotting. (B) Individual G418-resis- 
rant colonies from clone KTCTL 60 cells transfected with plakoglobin and the neo  r gene were analyzed for plakoglobin expression. The 
The Journal of Cell Biology, Volume 133, 1996  206 distribution of plakoglobin between the Triton X-100-soluble (s) and insoluble (i) fractions was determined in the parental clone (60) 
and in the plakoglobin-transfected clones 14, 13, and 9. (C) The expression of cadherin (CAD) (using a Pan-cadherin antibody), a-cate- 
nin (a-CAT), 13-catenin (13-CAT), desmoplakin II (DP), desmocollin 2 (DC), and desmoglein 2 (DG) by control KTCTL 60 cells and 
cells transfected with plakoglobin was examined by Western blotting. Only about half of the amount of protein was loaded from clone 
14 in C as compared to the other lanes. Cell morphology (D and F) and immunofluorescence with anti-plakoglobin antibody (E and G) 
of untransfected KTCTL 60 (D and E) and plakoglobin-transfected  cells (clone 14, F and G). M, MDCK cell extract. Bars: (D and F) 50 
~M; (E and G) 10 ~M. 
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Figure 7.  Tumorigenicity  of human renal carcinoma clones  ex- 
pressing  different levels  of plakoglobin.  KTCTL 60 clones  ex- 
pressing  different levels of plakoglobin (as shown  in Fig. 6 B) 
were injected into groups of five mice and the diameter of tumors 
was determined at the indicated times. The size of tumors formed 
by: (A) clones I, 4, 11, and 12 and (B) clones 3, 9, 13, and 14 was 
determined. As the shape of the tumors was spherical, the differ- 
ences in tumor mass formed by the plakoglobin expressing cells 
was much larger• For example, at 18 d, the tumor formed by clone 
13 was 18-fold smaller than the tumor mass formed by clone 9. 
Animals injected with clone 14 were tumor-free even after 3 me. 
that the plakoglobin- and [~-catenin-related molecule ar- 
madillo (Peifer and Weischaus, 1990; Peifer et al., 1991) is 
a segment polarity gene in Drosophila, and is part of the 
signaling pathway driven by the secreted glycoprotein wg 
(Bejsovec and Wieschaus, 1993), the homologue in verte- 
brates of the head axis determining protein wnt-1 (Sokol et 
el., 1991). Wnt-1 was also shown to elicit adhesion-related 
responses in plakoglobin expression  and  organization  in 
mammalian cells (Bradley et al., 1993; Hinck et el., 1994b). 
Furthermore, both 13-catenin  (Funayama et al., 1995) and 
plakoglobin mRNA overexpression (Karnovsky and Klym- 
kowsky, 1995) result in embryonic axis induction in Xeno- 
pus, with part of the molecules distributed in the cell nu- 
cleus.  It  remains  to  be  determined  whether  the  tumor 
suppressor activity of plakoglobin is exerted by an interac- 
tion with APC, or other signaling molecules, and to eluci- 
date  the  mechanisms by which  these  molecules  are  in- 
volved in bringing about the exit of ceils from S-phase. 
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